Vaxcyte (PCVX)
(Real Time Quote from BATS)
$82.96 USD
+1.33 (1.63%)
Updated Jul 22, 2024 12:02 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Vaxcyte, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1,080 | 931 | 246 | 386 | 59 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 16 | 11 | 10 | 3 | 3 |
Total Current Assets | 1,096 | 943 | 256 | 389 | 62 |
Net Property & Equipment | 80 | 10 | 8 | 3 | 3 |
Investments & Advances | 163 | 27 | 27 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 39 | 5 | 5 | 1 | 1 |
Total Assets | 1,408 | 1,006 | 324 | 393 | 66 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 10 | 7 | 30 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 124 | 25 | 17 | 17 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 145 | 41 | 29 | 47 | 11 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 167 | 53 | 40 | 47 | 12 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 160 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,165 | 1,476 | 583 | 544 | 3 |
Retained Earnings | -924 | -522 | -299 | -199 | -109 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,240 | 954 | 284 | 346 | 54 |
Total Liabilities & Shareholder's Equity | 1,408 | 1,006 | 324 | 393 | 66 |
Total Common Equity | 1,240 | 954 | 284 | 346 | -106 |
Shares Outstanding | 95.10 | 79.40 | 52.70 | 50.90 | NA |
Book Value Per Share | 13.04 | 12.01 | 5.39 | 6.79 | 0.00 |
Fiscal Year End for Vaxcyte, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 1,487 | 1,080 | 1,266 | 1,287 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 31 | 16 | 30 | 23 |
Total Current Assets | NA | 1,517 | 1,096 | 1,295 | 1,310 |
Net Property & Equipment | NA | 85 | 80 | 11 | 16 |
Investments & Advances | NA | 413 | 163 | 169 | 154 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 47 | 39 | 4 | 4 |
Total Assets | NA | 2,091 | 1,408 | 1,496 | 1,503 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 22 | 15 | 16 | 16 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 58 | 124 | 64 | 38 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 87 | 145 | 86 | 60 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 107 | 167 | 93 | 69 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 3,000 | 2,165 | 2,149 | 2,087 |
Retained Earnings | NA | -1,019 | -924 | -744 | -651 |
Other Equity | NA | 3 | 0 | -2 | -3 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 1,984 | 1,240 | 1,403 | 1,433 |
Total Liabilities & Shareholder's Equity | NA | 2,091 | 1,408 | 1,496 | 1,503 |
Total Common Equity | 0 | 1,984 | 1,240 | 1,403 | 1,433 |
Shares Outstanding | 108.80 | 108.70 | 95.10 | 93.80 | 93.70 |
Book Value Per Share | 0.00 | 18.25 | 13.04 | 14.95 | 15.30 |